INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,751,378 | +142.3% | 741,714 | +44.5% | 0.00% | – |
| Q2 2023 | $5,676,468 | -43.5% | 513,243 | -31.4% | 0.00% | -100.0% |
| Q1 2023 | $10,052,288 | +44.0% | 748,495 | +32.6% | 0.00% | +50.0% |
| Q4 2022 | $6,981,603 | -58.5% | 564,398 | -53.3% | 0.00% | -50.0% |
| Q3 2022 | $16,843,000 | +41.1% | 1,207,436 | +39.7% | 0.00% | +33.3% |
| Q2 2022 | $11,933,000 | +30.9% | 864,014 | +54.2% | 0.00% | +50.0% |
| Q1 2022 | $9,114,000 | -51.3% | 560,182 | -51.2% | 0.00% | – |
| Q4 2021 | $18,704,000 | +115.9% | 1,148,260 | +96.8% | 0.00% | – |
| Q3 2021 | $8,665,000 | +5.5% | 583,549 | +41.9% | 0.00% | – |
| Q2 2021 | $8,214,000 | -9.0% | 411,317 | +5.2% | 0.00% | -100.0% |
| Q1 2021 | $9,022,000 | -77.4% | 390,910 | -75.8% | 0.00% | -75.0% |
| Q4 2020 | $39,846,000 | +113.2% | 1,613,198 | +257.9% | 0.00% | 0.0% |
| Q3 2020 | $18,688,000 | -5.7% | 450,746 | +9.0% | 0.00% | 0.0% |
| Q2 2020 | $19,814,000 | -16.3% | 413,580 | +10.0% | 0.00% | -42.9% |
| Q1 2020 | $23,662,000 | -74.0% | 375,812 | -48.8% | 0.01% | -72.0% |
| Q4 2019 | $90,997,000 | +59.3% | 734,325 | -14.7% | 0.02% | +31.6% |
| Q3 2019 | $57,116,000 | -76.8% | 860,689 | -72.2% | 0.02% | -36.7% |
| Q2 2019 | $246,461,000 | +77.4% | 3,097,421 | +149.5% | 0.03% | -47.4% |
| Q1 2019 | $138,893,000 | +28.6% | 1,241,670 | +15.9% | 0.06% | +35.7% |
| Q4 2018 | $108,025,000 | -10.2% | 1,071,788 | +12.5% | 0.04% | +7.7% |
| Q3 2018 | $120,357,000 | +104.2% | 952,500 | +35.6% | 0.04% | +85.7% |
| Q2 2018 | $58,944,000 | +6.1% | 702,451 | -22.2% | 0.02% | +10.5% |
| Q1 2018 | $55,535,000 | -8.3% | 902,718 | -12.9% | 0.02% | -9.5% |
| Q4 2017 | $60,566,000 | -49.7% | 1,036,723 | -50.1% | 0.02% | -54.3% |
| Q3 2017 | $120,491,000 | +93.8% | 2,075,991 | +304.2% | 0.05% | +70.4% |
| Q2 2017 | $62,179,000 | -7.8% | 513,579 | -13.9% | 0.03% | -20.6% |
| Q1 2017 | $67,443,000 | -44.5% | 596,321 | -46.7% | 0.03% | -45.2% |
| Q4 2016 | $121,597,000 | -20.1% | 1,119,166 | +21.1% | 0.06% | -15.1% |
| Q3 2016 | $152,107,000 | -1.5% | 924,162 | -14.6% | 0.07% | -12.0% |
| Q2 2016 | $154,355,000 | +35.8% | 1,081,824 | +22.3% | 0.08% | +38.3% |
| Q1 2016 | $113,661,000 | -17.3% | 884,730 | -3.9% | 0.06% | -4.8% |
| Q4 2015 | $137,448,000 | -8.5% | 920,311 | +1.6% | 0.06% | -4.5% |
| Q3 2015 | $150,210,000 | -35.1% | 905,637 | -5.6% | 0.07% | -32.7% |
| Q2 2015 | $231,532,000 | -33.5% | 959,198 | -22.3% | 0.10% | -38.0% |
| Q1 2015 | $348,010,000 | +130.4% | 1,233,989 | +27.5% | 0.16% | +163.3% |
| Q4 2014 | $151,030,000 | -42.6% | 968,144 | -12.9% | 0.06% | -41.2% |
| Q3 2014 | $263,084,000 | +23.7% | 1,111,512 | +23.6% | 0.10% | +10.9% |
| Q2 2014 | $212,753,000 | +970.0% | 899,095 | +1391.2% | 0.09% | +922.2% |
| Q1 2014 | $19,884,000 | +7853.6% | 60,295 | +1544.3% | 0.01% | – |
| Q4 2013 | $250,000 | -14.7% | 3,667 | -13.5% | 0.00% | – |
| Q3 2013 | $293,000 | – | 4,241 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |